首页|UPLC-MS/MS测定人血浆中阿莫西林浓度及其在生物等效性研究中的应用

UPLC-MS/MS测定人血浆中阿莫西林浓度及其在生物等效性研究中的应用

扫码查看
目的 建立一套样品和沉淀剂用量更少,操作更简便的超高效液相色谱-串联质谱法(UPLC-MS/MS)测定人血浆中阿莫西林浓度,并应用于国产制剂阿莫西林胶囊与其参比制剂的生物等效性研究.方法 采用 Waters Acquity UPLC BEH C18 色谱柱(2.1 mm×50mm,1.7 μm),以0.05%甲酸水溶液(A)-含0.1%甲酸的75%甲醇水溶(B)为流动相,流速0.35 mL·min-1进行梯度洗脱,进样量1μL,柱温35 ℃,以ESI离子源、正离子MRM模式测定阿莫西林(m/z 366.1→114.0),阿莫西林-d4(m/z370.2→114.0)作为内标.血浆样品依次加入内标、甲醇沉淀蛋白后,取上清液稀释后进样检测.结果 阿莫西林在20~8000ng·mL-1与测定值线性关系良好,定量下限为20 ng·mL-1,质控样品批内、批间精密度CV≤3.9%,准确度相对偏差在标示值-1.9%~3.9%,提取回收率、专属性、基质效应、稳定性等各项指标均符合《中国药典》四部通则中生物样品定量分析方法验证指导原则.本方法被成功应用于健康受试者口服250 mg阿莫西林胶囊的生物等效性研究,在餐后给药状态下,受试制剂和参比制剂Cmax分别为(4922.16±967.16)和(5172.19±905.07)ng·mL-1,AUC0~12h 分别为(14 165.22±1686.79)和(13 869.53±1939.31)h·ng·mL-1;在空腹给药状态下,受试制剂和受试制剂Cmax分别为(6087.36±1766.53)和(5697.95±1768.73)ng·mL-1,AUC0~12h 分别为(15 081.27±2342.12)和(14 564.04±2364.83)h·ng·mL-1,受试制剂与参比制剂Cmax、AUC0~12h几何均值比的90%置信区间均落在80.00%~125.00%.结论 该方法灵敏度高、前处理过程简便,适用于血浆样品中阿莫西林的高通量分析;受试制剂阿莫西林胶囊与参比制剂具有生物等效性.
Determination of amoxicillin concentration in human plasma by UPLC-MS/MS and its application in bioequivalence study
Objective To establish a UPLC-MS/MS method with less sample and precipitant and easy operation to determine amoxicillin concentration in human plasma,and to use it in the bioequivalence study of amoxicillin capsules and their reference preparations.Methods A Waters Acquity UPLC BEH C18(2.1 mm × 50 mm,1.7 μm)column was used with the mobile phase consisting of 0.05%formic acid water(A)and 75%methanol solution(containing 0.1%formic acid)(B)in gradient elution.The flow rate was 0.35 mL·min-1 with the injection volume of 1 μL and the column temperature was 35 ℃.Amoxicillin(m/z 366.1 → 114.0)was detected by ESI ion source and positive ion MRM scanning mode,with amoxicillin-d4(m/z 370.2 → 114.0)as the internal standard.After adding the internal standard,the plasma protein was precipitated by methanol,the supernatants were diluted and measured.Results The linearity ranged 20~8000 ng·mL-1 and the lower limit of quantification was 20 ng·mL-1.The intra-day and inter-day precision CV of quality-control samples was≤3.9%,and the accuracy ranged-1.9%~3.9%in terms of relative error.The recovery rate,specificity,matrix effect and stability all met the guiding principles for verification of quantitative analysis of biological samples in the General Rules of Chinese Pharmacopoeia(four edition).The method was successfully applied to a bioequivalence study of amoxicillin orally disintegrating capsules containing 250 mg in healthy volunteers.In the fed test,the Cmax of the test or reference formulation of amoxicillin capsules was(4922.16±967.16)and(5172.19±905.07)ng·mL-1;AUC0~12h was(14 165.22±1686.79)and(13 869.53±1939.31)h·ng·mL-1.In the fasting test,the Cmax of the test or reference formulation of amoxicillin capsules was(6087.36±1766.53)and(5697.95±1768.73)ng·mL-1;AUC0~12h was(15 081.27±2342.12)and(14 564.04±2364.83)h·ng·mL-1.The 90%confidence intervals of the geometric mean ratios of Cmax,andAUC0~12h between the test and the reference formulation completely fell at 80.00%~125.00%.Conclusion The method is highly sensitive,simple and rapid,and is suitable for high throughput analysis of amoxicillin in the plasma sample.The test amoxicillin orally disintegrating capsules are bioequivalent to the reference capsules.

amoxicillinantimicrobialplasma concentrationbioequivalenceUPLC-MS/MS

唐维英、朱恒怡、李莎、杨姗姗、吴强

展开 >

四川省药品检验研究院国家药品监督管理局药物制剂体内外相关性技术研究重点实验室,成都 611731

四川尚锐分析检测有限公司,成都 610093

阿莫西林 抗菌药 血浆浓度 生物等效性 超高效液相色谱-串联质谱法

2024

中南药学
湖南省药学会

中南药学

CSTPCD
影响因子:0.736
ISSN:1672-2981
年,卷(期):2024.22(12)